Caffeine is one of the few supplements that have enough scientific evidence to state that can notably improve performance, as different remarkable organizations in the sports nutrition context have classified it as an ergogenic aid with strong evidence regarding its efficacy and that is apparently safe. The beneficial effect of this substance on physical and cognitive performance has been identified in aerobic and anaerobic efforts, including aerobic and muscular endurance, power, or strength. However, it seems that the benefits of caffeine are usually measured only by its effect on performance, while a comprehensive analysis of its impact on other aspects of the movement technique of the exercise is not considered. Therefore, although caffeine generates better performance, a null or negative effect may occur on technique execution. As such, some consequences might arise (e.g., an increase in injury risk or a decrease in energy efficiency). The objective of this randomized controlled trial is to assess the influence of caffeine on certain biomechanical parameters of the technique of physical exercises in circumstances without fatigue and under neuromuscular fatigue. The study hypothesis is that caffeine generates modifications in the technical execution of certain movements in fatigued and unfatigued circumstances due to its physiological effects, which may be beneficial for performance and injury prevention. The participants will have to attend 5 sessions (enrollment, familiarization, control, placebo, and caffeine), at least 7 days apart. In the last 3 sessions, different measurements will be done to their technique while jumping, squatting, and running, without fatigue and with it. Other data will be collected throughout the study to contextualize and analyze in more detail the obtained information.
Age range
18 Years – 30 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Knee flexion angle at the midstance while running.
Timeframe: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Ankle dorsiflexion angle at the midstance while running.
Timeframe: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Step rate while running.
Timeframe: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Contact time while running.
Timeframe: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Stride length while running.
Timeframe: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Flight time while running.
Timeframe: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Running performance modification.
Timeframe: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Hip angle while squatting, at the initial position, bottom position, and final position, and the eccentric and the concentric range of movement.
Timeframe: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Knee angle while squatting, at the initial position, bottom position, and final position, and the eccentric and the concentric range of movement.
Timeframe: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Ankle angle while squatting, at the initial position, bottom position, and final position, and the eccentric and the concentric range of movement.
Timeframe: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Execution time while squatting, for the eccentric and the concentric phases of the movement.
Timeframe: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Peak vertical force while squatting, for the eccentric and the concentric phases of the movement.
Timeframe: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Rate of force development while squatting, for the eccentric and the concentric phases of the movement.
Timeframe: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Squatting performance modification.
Timeframe: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Contralateral pelvic drop angle while jumping, at the initial contact of the landing phase.
Timeframe: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Knee valgus while jumping, at the initial contact and the deepest landing position of the landing phase, and the range of movement between these two moments.
Timeframe: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Unweighting phase duration while jumping (jumping phase).
Timeframe: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Braking phase duration while jumping (jumping phase).
Timeframe: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Propulsive phase duration while jumping (jumping phase).
Timeframe: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Relative peak power output while jumping (jumping phase).
Timeframe: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.
Jumping performance modification.
Timeframe: During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.